Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: A pilot study of these conditions with and without diabetes

Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer

Research output: Contribution to journalArticle

Abstract

Objective: This exploratory study seeks to identify distinct circulating immune signatures among patients having recurrent acute pancreatitis (RAP), chronic pancreatitis (CP), and pancreatic adenocarcinoma (PDAC). Methods: A retrospective analysis of human serum samples from collaborating institutions of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) was performed. Samples came from the North American Pancreatitis Studies 2 (NAPS2) cohort and the Pancreatic Adenocarcinoma Gene Environment Risk Study (PAGER) and were analyzed using a 62-plex Luminex assay in a blinded fashion. Group and pairwise comparisons were performed to identify unique immune signature panels and to calculate diagnostic utility using area under the curve analysis. Results: A total of 179 patients’ samples were included: 41 controls, 40 CP, 78 PDAC and 20 RAP patients, of which 20 controls, 20 CP, and 58 PDAC patients had diabetes mellitus (DM). A unique immune signature panel could discriminate RAP, CP, and PDAC from controls with an AUC range from 0.77 to 0.86 (95% CI range: 0.64–0.94), RAP from CP, and CP from PDAC with an AUC of 0.77 (95% CI 0.64–0.90) and 0.76 (95% CI 0.67–0.86), respectively. Furthermore, an immune signature panel could also discriminate PDAC-DM from DM controls with an AUC of 0.96 (95% CI: 0.93–1.00) Conclusion: This study identifies unique immune analytes that may serve as novel diagnostic and predictive non-invasive biomarkers of RAP, CP, and PDAC. Further validation is warranted in prospective cohorts as developed by the CPDPC.

Original languageEnglish (US)
JournalPancreatology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Chronic Pancreatitis
Pancreatic Neoplasms
Pancreatitis
Area Under Curve
Diabetes Mellitus
Adenocarcinoma
Cohort Studies
Biomarkers
Serum

Keywords

  • Biomarkers
  • Cytokines
  • Diabetes
  • Pancreatic cancer
  • Pancreatitis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Gastroenterology

Cite this

Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer : A pilot study of these conditions with and without diabetes. / Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.

In: Pancreatology, 01.01.2019.

Research output: Contribution to journalArticle

@article{29c5995f483d4c3c95f83a6dad8bffdc,
title = "Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: A pilot study of these conditions with and without diabetes",
abstract = "Objective: This exploratory study seeks to identify distinct circulating immune signatures among patients having recurrent acute pancreatitis (RAP), chronic pancreatitis (CP), and pancreatic adenocarcinoma (PDAC). Methods: A retrospective analysis of human serum samples from collaborating institutions of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) was performed. Samples came from the North American Pancreatitis Studies 2 (NAPS2) cohort and the Pancreatic Adenocarcinoma Gene Environment Risk Study (PAGER) and were analyzed using a 62-plex Luminex assay in a blinded fashion. Group and pairwise comparisons were performed to identify unique immune signature panels and to calculate diagnostic utility using area under the curve analysis. Results: A total of 179 patients’ samples were included: 41 controls, 40 CP, 78 PDAC and 20 RAP patients, of which 20 controls, 20 CP, and 58 PDAC patients had diabetes mellitus (DM). A unique immune signature panel could discriminate RAP, CP, and PDAC from controls with an AUC range from 0.77 to 0.86 (95{\%} CI range: 0.64–0.94), RAP from CP, and CP from PDAC with an AUC of 0.77 (95{\%} CI 0.64–0.90) and 0.76 (95{\%} CI 0.67–0.86), respectively. Furthermore, an immune signature panel could also discriminate PDAC-DM from DM controls with an AUC of 0.96 (95{\%} CI: 0.93–1.00) Conclusion: This study identifies unique immune analytes that may serve as novel diagnostic and predictive non-invasive biomarkers of RAP, CP, and PDAC. Further validation is warranted in prospective cohorts as developed by the CPDPC.",
keywords = "Biomarkers, Cytokines, Diabetes, Pancreatic cancer, Pancreatitis",
author = "{Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer} and Park, {Walter G.} and Liang Li and Savitri Appana and Wei Wei and Kimberly Stello and Andersen, {Dana K.} and Hughes, {Steven J.} and Whitcomb, {David C.} and Brand, {Randall E.} and Dhiraj Yadav and Aida Habtezion",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.pan.2019.11.008",
language = "English (US)",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer

T2 - A pilot study of these conditions with and without diabetes

AU - Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer

AU - Park, Walter G.

AU - Li, Liang

AU - Appana, Savitri

AU - Wei, Wei

AU - Stello, Kimberly

AU - Andersen, Dana K.

AU - Hughes, Steven J.

AU - Whitcomb, David C.

AU - Brand, Randall E.

AU - Yadav, Dhiraj

AU - Habtezion, Aida

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: This exploratory study seeks to identify distinct circulating immune signatures among patients having recurrent acute pancreatitis (RAP), chronic pancreatitis (CP), and pancreatic adenocarcinoma (PDAC). Methods: A retrospective analysis of human serum samples from collaborating institutions of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) was performed. Samples came from the North American Pancreatitis Studies 2 (NAPS2) cohort and the Pancreatic Adenocarcinoma Gene Environment Risk Study (PAGER) and were analyzed using a 62-plex Luminex assay in a blinded fashion. Group and pairwise comparisons were performed to identify unique immune signature panels and to calculate diagnostic utility using area under the curve analysis. Results: A total of 179 patients’ samples were included: 41 controls, 40 CP, 78 PDAC and 20 RAP patients, of which 20 controls, 20 CP, and 58 PDAC patients had diabetes mellitus (DM). A unique immune signature panel could discriminate RAP, CP, and PDAC from controls with an AUC range from 0.77 to 0.86 (95% CI range: 0.64–0.94), RAP from CP, and CP from PDAC with an AUC of 0.77 (95% CI 0.64–0.90) and 0.76 (95% CI 0.67–0.86), respectively. Furthermore, an immune signature panel could also discriminate PDAC-DM from DM controls with an AUC of 0.96 (95% CI: 0.93–1.00) Conclusion: This study identifies unique immune analytes that may serve as novel diagnostic and predictive non-invasive biomarkers of RAP, CP, and PDAC. Further validation is warranted in prospective cohorts as developed by the CPDPC.

AB - Objective: This exploratory study seeks to identify distinct circulating immune signatures among patients having recurrent acute pancreatitis (RAP), chronic pancreatitis (CP), and pancreatic adenocarcinoma (PDAC). Methods: A retrospective analysis of human serum samples from collaborating institutions of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) was performed. Samples came from the North American Pancreatitis Studies 2 (NAPS2) cohort and the Pancreatic Adenocarcinoma Gene Environment Risk Study (PAGER) and were analyzed using a 62-plex Luminex assay in a blinded fashion. Group and pairwise comparisons were performed to identify unique immune signature panels and to calculate diagnostic utility using area under the curve analysis. Results: A total of 179 patients’ samples were included: 41 controls, 40 CP, 78 PDAC and 20 RAP patients, of which 20 controls, 20 CP, and 58 PDAC patients had diabetes mellitus (DM). A unique immune signature panel could discriminate RAP, CP, and PDAC from controls with an AUC range from 0.77 to 0.86 (95% CI range: 0.64–0.94), RAP from CP, and CP from PDAC with an AUC of 0.77 (95% CI 0.64–0.90) and 0.76 (95% CI 0.67–0.86), respectively. Furthermore, an immune signature panel could also discriminate PDAC-DM from DM controls with an AUC of 0.96 (95% CI: 0.93–1.00) Conclusion: This study identifies unique immune analytes that may serve as novel diagnostic and predictive non-invasive biomarkers of RAP, CP, and PDAC. Further validation is warranted in prospective cohorts as developed by the CPDPC.

KW - Biomarkers

KW - Cytokines

KW - Diabetes

KW - Pancreatic cancer

KW - Pancreatitis

UR - http://www.scopus.com/inward/record.url?scp=85076558679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076558679&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2019.11.008

DO - 10.1016/j.pan.2019.11.008

M3 - Article

C2 - 31791885

AN - SCOPUS:85076558679

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

ER -